DOCSLIB.ORG

Comparison of the Effects of Three Insulinotropic Drugs on Plasma Insulin Levels After a Standard Meal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparison of the Effects of Three Insulinotropic Drugs on Plasma Insulin Levels After a Standard Meal Clinical Care/Education/Nutrition ORIGINAL ARTICLE Comparison of the Effects of Three Insulinotropic Drugs on Plasma Insulin Levels After a Standard Meal 1 2 LAWRENCE S. COZMA, MRCP KIRSTEN W. LANGENDORG, MSC both chronic (6) and acute hyperglycemia 1 3 STEPHEN D. LUZIO, PHD THOMAS PIEBER (7) have been shown to worsen the func- 1 1 GARETH J. DUNSEATH, BSC DAVID R. OWENS, MD, FRCP tion of the endothelium. Recent prospective studies have at- tempted to assess the effects of fasting and postprandial hyperglycemia independent OBJECTIVE — To compare the effects of repaglinide, glipizide, and glibenclamide on insulin of each other. Postprandial hyperglyce- secretion and postprandial glucose after a single standard 500-kcal test meal. mia might be more important than fasting RESEARCH DESIGN AND METHODS — A total of 12 type 2 diabetic patients with hyperglycemia in predicting CVD (8). However, despite indisputable evidence early diabetes (mean HbA1c of 6.1%) and 12 matched control subjects were enrolled in this randomized, double-blind, crossover trial. Subjects received placebo, 2 mg repaglinide, 5 mg that better diabetes control reduces the glipizide, and 5 mg glibenclamide in a random fashion during the trial. Administration of each incidence of microvascular complica- drug was followed by a single standard 500-kcal test meal. A washout period of 7–12 days existed tions, a reduction in the risk of developing between the four study visits. CVD has not been proven convincingly. Hemoglobin glycosylation is influ- RESULTS — All three drugs were equally effective on the total prandial insulin secretion (area enced by both fasting and postprandial under the curve [AUC] –15 to 240 min). However, clear differences were noted in the early glucose; the latter is more strongly corre- insulin secretion (AUC –15 to 30 min); both repaglinide and glipizide increased secretion in lated with HbA values (9). Therefore, nondiabetic subjects by ϳ61 and 34%, respectively, compared with placebo. In the diabetic 1c patients, the difference versus placebo was 37 and 47%, respectively. The difference between targeting the postprandial glucose level glipizide and glibenclamide reached significance in both groups of subjects, whereas repaglinide when elevated seems logical and has been was more effective than glibenclamide only in the healthy nondiabetic subject group. All three shown to achieve better control than fo- drugs were effective in decreasing total glucose AUC in the nondiabetic and diabetic population. cusing on the fasting glucose level alone In the nondiabetic subjects, however, repaglinide was significantly more effective than gliben- (10). clamide. The differences disappeared in the diabetic subjects, probably as a result of increased Postprandial hyperglycemia is gener- prevalence of insulin resistance in this group. ated by a combination of impaired pan- creatic insulin secretion, unsuppressed CONCLUSIONS — Repaglinide and glipizide but not glibenclamide significantly enhanced ␤ hepatic glucose production, and reduced the early insulin secretion in both nondiabetic and diabetic subjects with preserved -cell glucose uptake in the periphery (11). In- function after a single standard meal. sulin secretion in normal subjects has a Diabetes Care 25:1271–1276, 2002 characteristic biphasic pattern, with an early phase lasting Ͻ10 min after food ingestion followed by a more sustained later phase of insulin release, which par- ardiovascular disease (CVD) is the (3). Dysfunction of the vascular endothe- allels the glucose absorption from the gut most important cause of morbidity lium is present early in the history of dia- (12). In type 2 diabetes, there is a loss of and mortality in type 2 diabetes (1). betes (4) and has been implicated in C the early phase and a delayed, blunted, The classical risk factors of hypertension, atherogenesis. Insulin resistance and its smoking, increased LDL, and reduced associated features are a major determi- and consequently more prolonged late HDL with increased triglycerides (2) ac- nant of the abnormal endothelial function phase (13). These changes occur very count for Ͻ50% of the excess risk of CVD in the prediabetic stages (5). However, early in the natural history of this syn- drome, and the degree of blunting relates ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● to the fasting plasma glucose, the so- From the 1Diabetes Research Unit, University Hospital of Wales, College of Medicine, South Glamorgan, called “Starling curve” of the pancreas Wales; 2Novo Nordisk A/S, Bagsvaerd, Denmark; and 3Med Universitatsklinik Graz, Graz, Austria. (14). The early-phase loss contributes to a Address correspondence and reprint requests to Dr. L. S. Cozma, Diabetes Research Unit, University lack of early suppression of the glucagon Hospital of Wales, College of Medicine, First Floor, Academic Centre, Llandough Hospital and Community NHS Trust, Penlan Rd., Penarth, South Glamorgan CF642XX. E-mail: [email protected]. secretion after ingestion of carbohydrates Received for publication 4 November 2001 and accepted in revised form 26 March 2002. (15), which in turn leads to continuing Thomas R. Pieber has received honoraria for speaking engagements from Novo Nordisk A/S. hepatic glucose production and an accen- Abbreviations: AUC, area under the curve; CVD, cardiovascular disease; KATP, ATP-sensitive potas- tuation of the hyperglycemia (16). A loss sium. A table elsewhere in this issue shows conventional and Syste`me International (SI) units and conversion of the early phase of secretion has been factors for many substances. shown to cause postprandial glucose in- See accompanying editorial on p. 1472. tolerance in nondiabetic subjects (17). In DIABETES CARE, VOLUME 25, NUMBER 8, AUGUST 2002 1271 Effects of insulinotropic drugs on plasma insulin levels Table 1—Baseline characteristics cross-reacted Ͻ2% with insulin and ϳ100% with proinsulin. Type 2 diabetic subjects Nondiabetic subjects Statistical analysis n 12 12 Data were analyzed using SAS 6.11 soft- Age (years) 57.0 Ϯ 8.7 56.3 Ϯ 9.3 ware on a UNIX platform. Metabolic pa- Men/women (n) 7 (58) / 5 (42) 7 (58) / 5 (42) rameters with a normal distribution are BMI 29.5 Ϯ 3.2 29 Ϯ 1.9 presented as means with SD or 95% CI. Ϯ Ϯ ϭ HbA1c baseline 6.1 1.2* 4.6 0.4 (n 11)* Nonnormally distributed data parameters Duration of diabetes (years min–max) 2.6 (0.5–6.6) N/A are shown as median with minimum and Fasting glucose baseline (mmol/l) 7.83 Ϯ 0.7* 4.84 Ϯ 0.2* maximum also given. Area under the Data are means Ϯ SD and n (%). *P Ͻ 0.05. curve (AUC) was calculated using the trapezoidal rule. Fasting levels for glu- cose, insulin, and C-peptide were calcu- Ϫ type 2 diabetes, restoration of the early tients had good control with HbA1c lated by averaging premeal values ( 30, phase using short-acting insulin analogs Յ6.5%, two had borderline control with Ϫ20, Ϫ15, and 0 min). Insulin secretion significantly improves the glucose toler- HbA1c between 6.5 and 7.5%, and two was analyzed as early phase, terminal Ͼ ance by reducing the endogenous glucose had poor control with HbA1c 7.5%. phase, and total insulin secretion by cal- output (18). However, despite the inhib- The treatment period started within culating insulin AUCs for the first 30 min, itory effects on the hepatic glucose pro- 30 days after the screening visit and con- the last 120 min, and the total 240 min, duction, the impaired glucose utilization sisted of four visits with washout periods respectively. AUC and the maximal by the insulin-resistant tissues remains of 7–12 days between them. A follow-up plasma concentration (Cmax) were loga- unchanged. visit was conducted 7–12 days after the rithmically transformed to obtain nor- Among the agents available for man- last treatment day. The maximum dura- mally distributed data. The transformed agement of type 2 diabetes, only ␣-glyco- tion of participation for each subject was end points were compared across groups sidase inhibitors (19) and short-acting 77 days from the first visit to the last visit. using ANOVA for a crossover design ac- insulinotropic agents such as repaglinide After a 10-h overnight fast, an intra- counting for sequence of treatment, sub- (20) and nateglinide (21) have definitely venous cannula was inserted and saline ject (within a treatment sequence), visit been shown to impact the postprandial infusion was started. Each subject re- (period), and treatment. Wilcoxon’s glucose levels. ceived placebo, 2 mg repaglinide, 5 mg signed-rank test was used to compare the The purpose of this study was to com- glipizide, and 5 mg glibenclamide in a individual groups. To account for multi- pare the effects on the ␤-cell function of random fashion. Administration of the ple comparisons, the Bonferroni method three insulinotropic agents available for drug was followed 15 min later by a stan- was applied. Using an overall level of sig- the treatment of patients with type 2 dia- dard 500-kcal meal tolerance test (55% nificance of 0.05, the nominal level of sig- betes: repaglinide, glipizide, and gliben- carbohydrate, 30% fat, and 15% protein). nificance was 0.05/3 ϭ 0.02 with three clamide. Blood sampling for glucose, insulin, and comparisons. C-peptide was performed at –30, –20, RESEARCH DESIGN AND –15, and 0 min before the meal. Postmeal RESULTS — All 24 subjects who were METHODS samples were collected every 10 min dur- recruited completed the study. Demo- ing the first hour, every 15 min during the graphic and glycemic parameters of the Study design second hour, and hourly thereafter for a study population are shown in Table 1. This study was a randomized, double- total of 4 h. The only significant differences between blind, crossover trial performed at two the diabetic population and the control centers, one in the U.K. and the second in group were in the fasting glucose and the Austria. A total of 12 diet-treated type 2 Analytical methods HbA1c levels.
Load more

Recommended publications
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • Diabetes Medications: Oral Medications
    Diabetes Medications: Oral Medications Medication Types 1. Biguanides 2. Sulfonylureas 3. Thiazolidinediones (TZDs) 4. Alpha-Glucosidase Inhibitors 5. D-Phenylalanine Meglitinides 6. SGLT-2 inhibitors 7. DPP-4 inhibitors 8. Combination Oral Medications 1. Biguanides This works by lowering blood glucose by reducing the amount of glucose produced by the liver and helping the body respond better to the insulin made in the pancreas Metformin can be used with diet and exercise or with other agents, diet, and exercise. Types of Biguanides: • Metformin (Glucophage) 500mg/1000mg • Metformin (Glucophage XR) 500mg/1000mg • Fortamet (extended release) 500mg/1000mg • Riomet (oral solution) 500mg/5ml Side Effects: • Cramping • Gas • Diarrhea • Taking the pill before meals may decrease stomach upset 2. Sulfonylureas Sulfonylureas stimulate the pancreas to produce insulin and cause the body to respond better to the insulin it does produce. Sulfonylureas can be used alone or in combination with other medications. Types of Sulfonylureas: • Glimepiride (Amaryl) • Glipizide (Glucotrol, Glucotrol XL) • Glyburide (Diabeta, Micronase) • Glyburide, micronized (Glynase) • Tolbutamide (Orinase) 1st generation • Tolazamide (Tolinase) 1st generation • Acetohexamide (Dymelor) 1st generation • Chlorpropamide (Diabinese) 1st generation Side Effects: • Hypoglycemia • Upset stomach • Weight gain • Skin rash 3. Thiazolidinediones (TZDs) TZDs primarily reduce insulin resistance by improving target cell response (sensitivity) to insulin. They also can decrease glucose output from the liver and increase glucose disposal in the skeletal muscles. Types of TZDs: • Pioglitazione (Actos) 15-45 mg Actos may be taken with or without food • Avandia—off the market Side Effects: • Jaundice • Nausea and vomiting • Stomach pain • Dark urine • Swelling • These medicines are generally safe and do not cause hypoglycemia when used alone.
    [Show full text]
  • Orange Book Patent Listing Dispute List
    Patent Listing Disputes Current through September 10, 2021 Established Drug Product Due Date for NDA Holder NDA Holder NDA Number NDA Holder Strength(s) Relevant U.S. Patent Number(s) Type of Patent Claim Original Use Code (if applicable) Revised Use Code (if applicable) Dispute Outcome Name Response Response Date Disputes Not Related to epinephrine 205029 Belcher 1mg/mL 10,004,700 and 10,039,728 N/A N/A 7/24/2021 Pending Pending Use Code 7 mg 14 mg 8,168,209, 8,173,708, 8,283,379, Disputes Not Related to memantine hydrochloride 22525 Allergan Sales LLC N/A N/A 5/28/2021 5/28/2021 Patent Listing Updated 21 mg 8,329,752, 8,362,085 and 8,598,233 Use Code 28 mg 0.1 mg Disputes Not Related to epinephrine 201739 Kaleo Inc 0.15 mg 10,824,938 N/A N/A 2/28/2021 2/3/2021 Patent Listing Updated Use Code 0.3 mg Disputes Not Related to netarsudil and latanoprost 208259 Aerie Pharms Inc 0.02%/0.005% 10,654,844 N/A N/A 11/18/2020 10/30/2020 Patent Listing Updated Use Code Disputes Not Related to netarsudil 208254 Aerie Pharms Inc 0.02% 10,654,844 N/A N/A 11/18/2020 10/30/2020 Patent Listing Updated Use Code U-2869: IV Administration of cangrelor before U-2979: Method comprising IV administration PCI and continuous infusion for at least 2 of cangrelor before PCI then continuous hours or the duration of the PCI and, during infusion for at least 2 hours or the duration of cangrelor 204958 Chiesi 50 mg/vial 8,680,052 Method of Use 11/8/2020 11/3/2020 Patent Listing Updated or after the continuous infusion, PCI and, during or after continuous infusion,
    [Show full text]
  • Medication Choice Diabetes
    Weight Change Low Blood Sugar Blood Sugar Considerations (Hypoglycemia) Blood(A1c Reduction) Sugar Weight Change Low Blood Sugar (A1c Reduction) Considerations (Hypoglycemia) Metformin Metformin Metformin 1 – 2% Metformin In the rst few weeks after starting Metformin, patients may have some nausea, indigestion or diarrhea. None No Severe Risk Minor = 0 – 1% Insulin There are no other side effects associated with Insulin. Insulin Insulin Insulin Unlimited % Pioglitazone 4 to 6 lb. gain Over time, 10 in 100 people may have fluid retention Severe = 1 – 3% Minor = 30 – 40% (edema) while taking the drug. For some it may be as little as ankle swelling. For others, fluid may build up Pioglitazone 1% in the lungs making it difficult to breathe. This may Pioglitazone Pioglitazone resolve after you stop taking the drug. 10 in 100 people at risk of bone fractures who use this drug will have More than 2 to 6 lb. gain a bone fracture in the next 10 years. There appears to No Severe Risk Minor = 1 – 2% be a slight increase in the risk of bladder cancer with Liraglutide/ 0.5 – 1% this drug. Liraglutide/Exenatide Liraglutide/Exenatide Exenatide Liraglutide/Exenatide Some patients may have nausea or diarrhea. In some 3 to 6 lb. loss cases, the nausea may be severe enough that a patient No Severe Risk Minor = 0 – 1% has to stop taking the drug. There are reports of pain in the abdomen that may be caused by inammation Sulfonylureas Sulfonylureas Sulfonylureas 1 – 2% of the pancreas with these agents. Glipizide, Glimepiride, Glyburide Glipizide, Glimepiride, Glyburide Glipizide, Glimepiride, Glyburide Sulfonylureas 2 to 3 lb.
    [Show full text]
  • Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly with Insulin Secretagogues
    Research Letter | Diabetes and Endocrinology Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly With Insulin Secretagogues Young Hee Nam, PhD; Colleen M. Brensinger, MS; Warren B. Bilker, PhD; James H. Flory, MD; Charles E. Leonard, MSCE, PharmD; Sean Hennessy, PhD, PharmD Introduction + Supplemental content Serious hypoglycemia is a major, potentially fatal adverse event caused by insulin secretagogues.1 Author affiliations and article information are Previous case reports suggested that calcium-channel blockers (CCBs) might reduce the risk of listed at the end of this article. serious hypoglycemia in patients with hyperinsulinemic hypoglycemia.2,3 However, the association of serious hypoglycemia and CCBs used with insulin secretagogues has remained unclear. Because insulin secretion by the pancreas is mediated by calcium influx in beta cells through calcium channels,4 we conducted a population-based observational study on the hypothesis that concomitant use of CCBs may be associated with reduced rates of serious hypoglycemia in insulin secretagogue users. Methods This self-controlled case series study was approved by the institutional review board of the University of Pennsylvania, which waived the requirement for informed consent because the use or disclosure of the protected health information involved no more than minimal risk to the privacy of individuals, and the research could not practicably be conducted without the waiver or alteration and without access to and use of the protected health information. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline. We used claims data from the Medicaid programs of 5 US states (California, Florida, New York, Ohio, and Pennsylvania, encompassing more than a third of the nationwide Medicaid population), supplemented with Medicare claims for dual enrollees, from January 1, 1999, to December 31, 2011, and used the self- controlled case series design.
    [Show full text]
  • PRANDIN® (Repaglinide) Tablets (0.5, 1, and 2 Mg) Rx Only
    PRANDIN® (repaglinide) Tablets (0.5, 1, and 2 mg) Rx only DESCRIPTION PRANDIN® (repaglinide) is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM). Repaglinide, S(+)2-ethoxy-4(2((3-methyl-1-(2-(1-piperidinyl) phenyl)- butyl) amino)-2-oxoethyl) benzoic acid, is chemically unrelated to the oral sulfonylurea insulin secretagogues. The structural formula is as shown below: CH3 O OH H3C O N O H N CH3 Repaglinide is a white to off-white powder with molecular formula C27 H36 N2 O4 and a molecular weight of 452.6. PRANDIN tablets contain 0.5 mg, 1 mg, or 2 mg of repaglinide. In addition each tablet contains the following inactive ingredients: calcium hydrogen phosphate (anhydrous), microcrystalline cellulose, maize starch, polacrilin potassium, povidone, glycerol (85%), magnesium stearate, meglumine, and poloxamer. The 1 mg and 2 mg tablets contain iron oxides (yellow and red, respectively) as coloring agents. CLINICAL PHARMACOLOGY Mechanism of Action Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta (ß) cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations. Repaglinide closes ATP-dependent potassium channels in the ß-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the ß-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.
    [Show full text]
  • Sulfonylureas
    Therapeutic Class Overview Sulfonylureas INTRODUCTION In the United States (US), diabetes mellitus affects more than 30 million people and is the 7th leading cause of death (Centers for Disease Control and Prevention [CDC] 2018). Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and is characterized by elevated fasting and postprandial glucose concentrations (American Diabetes Association [ADA] 2019[a]). It is a chronic illness that requires continuing medical care and ongoing patient self-management education and support to prevent acute complications and to reduce the risk of long-term complications (ADA 2019[b]). ○ Complications of T2DM include hypertension, heart disease, stroke, vision loss, nephropathy, and neuropathy (ADA 2019[a]). In addition to dietary and lifestyle management, T2DM can be treated with insulin, one or more oral medications, or a combination of both. Many patients with T2DM will require combination therapy (Garber et al 2019). Classes of oral medications for the management of blood glucose levels in patients with T2DM focus on increasing insulin secretion, increasing insulin responsiveness, or both, decreasing the rate of carbohydrate absorption, decreasing the rate of hepatic glucose production, decreasing the rate of glucagon secretion, and blocking glucose reabsorption by the kidney (Garber et al 2019). Pharmacologic options for T2DM include sulfonylureas (SFUs), biguanides, thiazolidinediones (TZDs), meglitinides, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, amylinomimetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors, combination products, and insulin (Garber et al 2019). SFUs are the oldest of the oral antidiabetic medications, and all agents are available generically. The SFUs can be divided into 2 categories: first-generation and second-generation.
    [Show full text]
  • MRI Evidence That Glibenclamide Reduces Acute Lesion Expansion in a Rat Model of Spinal Cord Injury
    Spinal Cord (2013) 51, 823–827 OPEN & 2013 International Spinal Cord Society All rights reserved 1362-4393/13 www.nature.com/sc ORIGINAL ARTICLE MRI evidence that glibenclamide reduces acute lesion expansion in a rat model of spinal cord injury JM Simard1,2,3, PG Popovich4, O Tsymbalyuk1, J Caridi1, RP Gullapalli5, MJ Kilbourne6 and V Gerzanich1 Study design: Experimental, controlled, animal study. Objectives: To use non-invasive magnetic resonance imaging (MRI) to corroborate invasive studies showing progressive expansion of a hemorrhagic lesion during the early hours after spinal cord trauma and to assess the effect of glibenclamide, which blocks Sur1-Trpm4 channels implicated in post-traumatic capillary fragmentation, on lesion expansion. Setting: Baltimore. Methods: Adult female Long–Evans rats underwent unilateral impact trauma to the spinal cord at C7, which produced ipsilateral but not contralateral primary hemorrhage. In series 1 (six control rats and six administered glibenclamide), hemorrhagic lesion expansion was characterized using MRI at 1 and 24 h after trauma. In series 2, hemorrhagic lesion size was characterized on coronal tissue sections at 15 min (eight rats) and at 24 h after trauma (eight control rats and eight administered glibenclamide). Results: MRI (T2 hypodensity) showed that lesions expanded 2.3±0.33-fold (Po0.001) during the first 24 h in control rats, but only 1.2±0.07-fold (P40.05) in glibenclamide-treated rats. Measuring the areas of hemorrhagic contusion on tissue sections at the epicenter showed that lesions expanded 2.2±0.12-fold (Po0.001) during the first 24 h in control rats, but only 1.1±0.05-fold (P40.05) in glibenclamide-treated rats.
    [Show full text]
  • Oregon Drug Use Review / Pharmacy & Therapeutics Committee
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Oregon Drug Use Review / Pharmacy & Therapeutics Committee Thursday, July 26, 2018 1:00 - 5:00 PM HP Conference Room 4070 27th Ct. SE Salem, OR 97302 MEETING AGENDA NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9). I. CALL TO ORDER 1:00 PM A. Roll Call & Introductions R. Citron (OSU) B. Conflict of Interest Declaration R. Citron (OSU) C. Approval of Agenda and Minutes T. Klein (Chair) D. Department Update T. Douglass (OHA) E. Legislative Update T. Douglass (OHA) F. Mental Health Clinical Advisory Group Discussion K. Shirley (MHCAG) 1:40 PM II. CONSENT AGENDA TOPICS T. Klein (Chair) A. P&T Methods B. CMS and State Annual Reports C. Quarterly Utilization Reports 1. Public Comment III. DUR ACTIVITIES 1:45 PM A. ProDUR Report R. Holsapple (DXC) B. RetroDUR Report D. Engen (OSU) C. Oregon State Drug Reviews K. Sentena (OSU) 1. A Review of Implications of FDA Expedited Approval Pathways, Including the Breakthrough Therapy Designation IV.
    [Show full text]
  • Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes
    Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes Type 2 Diabetes ranges from predominantly insulin resistant with relative insulin deficiency to predominantly an insulin secretory defect with insulin resistance, American Diabetes Association, 2010. (ICD 9 code 250.0) Prevalence • 23.6 million Americans have diabetes – 7.8% of U.S. population. Of these, 5.7 million do not know they have the disease. • 1.6 million people ≥20 years of age are diagnosed with diabetes annually. • 90–95% of diabetic patients have Type 2 Diabetes. Manifestations Clinical of untreated diabetes • High blood glucose level • Excessive thirst • Frequent urination • Weight loss • Fatigue Oral • Increased risk of dental caries due to salivary hypofunction • Accelerated tooth eruption with increasing age • Gingivitis with high risk of periodontal disease (poor control increases risk) • Salivary gland dysfunction leading to xerostomia • Impaired or delayed wound healing • Taste dysfunction • Oral candidiasis • Higher incidence of lichen planus Other Potential Disorders/Concerns • Ketoacidosis, kidney failure, gastroparesis, diabetic neuropathy and retinopathy • Poor circulation, increased occurrence of infections, and coronary heart disease Management Medication The list of medications below are intended to serve only as a guide to facilitate the dental professional’s understanding of medications that can be used for Type 2 Diabetes. Medical protocols can vary for individuals with Type 2 Diabetes from few to multiple medications. ACTION TYPE BRAND NAME/GENERIC SIDE EFFECTS Enhance insulin Sulfonylureas Glipizide (Glucotrol) Angioedema secretion Glyburide (DiaBeta, Fluconazoles may increase the Glynase, Micronase) hypoglycemic effect of glipizide Glimepiride (Amaryl) and glyburide. Tolazamide (Tolinase, Corticosteroids may produce Diabinese, Orinase) hyperglycemia. Floxin and other fluoroquinolones may increase the hypoglycemic effect of sulfonylureas.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Nateglinide Item No. 23320 CAS Registry No.: 105816-04-4 Formal Name: N-[[trans-4-(1-methylethyl)cyclohexyl] O OH carbonyl]-D-phenylalanine Synonyms: A-4166, SDZ-DJN 608 O MF: C H NO 19 27 3 N FW: 317.4 Purity: ≥98% H UV/Vis.: λmax: 207 nm Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Nateglinide is supplied as a crystalline solid. A stock solution may be made by dissolving the nateglinide in the solvent of choice. Nateglinide is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of nateglinide in these solvents is approximately 30 mg/ml. Description Nateglinide is a hypoglycemic agent.1-3 It induces insulin and somatostatin release from perfused rat pancreas when used at concentrations ranging from 0.03 to 3 μM.1 Nateglinide (3 µM) increases intracellular calcium levels in isolated rat pancreatic β cells, an effect that can be inhibited by the L-type calcium channel blocker nitrendipine (Item No. 17549). Nateglinide-induced secretion of insulin and somatostatin and calcium influx is also reversed by the potassium channel activator diazoxide (Item No. 14576). Oral administration of nateglinide (1.6 mg/kg) reduces blood glucose levels by 20% in fasted mice.2 It also decreases blood glucose levels in an oral glucose tolerance test in normal rats, genetically diabetic KK mice, and a rat model of diabetes induced by streptozotocin (STZ; Item No.
    [Show full text]
  • New Therapeutic Agents Marketed in 2014: Part 1 Daniel A
    CPE New therapeutic agents marketed in 2014: Part 1 Daniel A. Hussar Objective: To provide information regarding the most important properties of Daniel A. Hussar, PhD, is Remington Professor of Pharmacy, Philadelphia College new therapeutic agents that have been marketed in 2014. of Pharmacy, University of the Sciences in Data sources: Product labeling supplemented selectively with published studies Philadelphia. and drug information reference sources. Development: This home-study CPE activity Data synthesis: Seven new therapeutic agents that were marketed in the United was developed by the American Pharmacists States in early 2014 are considered in this first of a four-part series: umeclidinium Association. bromide/vilanterol trifenatate, perampanel, eslicarbazepine acetate, apremilast, dapagliflozin propanediol, avanafil, and bazedoxifene/conjugated estrogens. In- dications and information on dosage and administration for these agents are re- viewed, as are the most important pharmacokinetic properties, drug interactions, and other precautions. Practical considerations for use of these new agents are also discussed. When possible, properties of the new drugs are compared with those of older agents marketed for the same indications. Conclusion: Umeclidinium/vilanterol is the first combination formulation for oral inhalation to include both a long-acting muscarinic antagonist and a long-acting beta-2-adrenergic agonist for the maintenance treatment of patients with chronic ob- structive pulmonary disease. Both perampanel and eslicarbazepine have been ap- proved as adjunctive treatment for patients with partial-onset seizures. Perampanel has a unique mechanism of action whereas eslicarbazepine has properties that are most similar to those of oxcarbazepine. Apremilast is indicated for the treatment of patients with active psoriatic arthritis and is effective following oral administra- tion.
    [Show full text]